Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025

One-year data from CAHtalyst™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia Results build upon previously reported one-year data from CAHtalyst™ Pediatric study SAN DIEGO, July...